Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study Background: Second-line irinotecan-based chemotherapy is commonly used in metastatic colorectal cancers after first-line oxaliplatin-based chemotherapy. No standard schedule of irinotecan has been established in this situation.
introduction
Colorectal cancer is the second leading cause of mortality in Western countries [1] . Approximately half of all patients with colorectal cancer develop metastatic disease. First-line therapy of advanced colorectal cancer has moved from 5-fluorouracil (5-FU) with leucovorin (LV) or oral fluoropyrimidines to combination of fluoropyrimidines with oxaliplatin or irinotecan [2] [3] [4] [5] , alongside the introduction of bevacizumab [6] . The FOLFOX4 regimen has become established as a standard first-line therapy for advanced disease after the European C95 and the USA N9741 studies, which demonstrated superiority over LV/5-FU and LV/5-FU bolus and irinotecan (IFL), respectively [2, 4] . OPTIMOX1 has shown that stopping oxaliplatin after six cycles followed by simplified LV5-FU2 (LV 200 mg/m 2 day 1, 5-FU bolus 400 mg/ m 2 day 1 followed by a 36-h 5-FU continuous infusion 2400 mg/m 2 ) alone achieves the same efficacy results, progressionfree survival (PFS) and overall survival (OS), to continuing oxaliplatin until progression or toxicity. Furthermore, discontinuing oxaliplatin after the sixth cycle greatly reduced the risk of grade 3-4 toxicity.
Irinotecan, a campthotecin analogue, has definite activity against advanced metastatic colorectal cancer both in chemotherapy-naive and after 5-FU failure [3, 5, 7, 8] . However, few data are available about second-line irinotecanbased chemotherapy in patients previously treated with frontline FOLFOX, and no irinotecan-based regimen has been established as a standard in these patients. The FOLFIRI-1 regimen is a combination of irinotecan 180 mg/m 2 day 1, combined with simplified LV5-FU2 ( Figure 1 ) [9] . In a phase III trial, single-agent irinotecan achieved a 4.4% response rate with 2.6 months PFS after oxaliplatin-based first-line chemotherapy [10] . The FOLFIRI-1 regimen has been recently reported to offer superior activity to two other irinotecan-based regimens (mIFL and CapeIRI) [11] . However, the FOLFIRI-1 regimen achieved a 4% response rate with 2.5 months PFS in FOLFOX-pretreated patients [10] .
In vitro studies suggested that the irinotecan and 5-FU synergy could be sequence dependent and reported a higher cytotoxicity when irinotecan was administered before 5-FU [12] [13] [14] . Clinical data are less documented. In a randomized phase II study, a higher cytotoxicity has been reported when irinotecan was administered after 5-FU [15] . Prompted by the poor efficacy of the FOLFIRI-1 regimen and the supposed schedule-dependent activity of irinotecan, the GERCOR has designed and tested two regimens using this sequencedependent synergy. In the FOLFIRI-2 regimen, irinotecan was fully delivered (180 mg/m 2 ) at the end of 5-FU infusion, on day 3. In a phase II study, this regimen was found to be active but too toxic [16] . In the FOLFIRI-3 regimen, irinotecan is then administered as two infusions: half dose before 5-FU and half dose at the end of the 5-FU infusion ( Figure 1) . A multicenter phase II study, carried on FOLFOX-pretreated patients, reported a 23% response rate and a 4.7-month PFS with acceptable toxic effects [17] . Another group also reported a 4.5-month PFS with FOLFIRI-3 used after irinotecan and/or oxaliplatin-based regimens and suggested that fractionated irinotecan administration might enhance the clinical benefit of this molecule [18] . Based on these data, the FOLFIRI-3 was commonly used in FOLFOX-pretreated cancer patients by investigators participating to the GERCOR studies. However, it has not been compared with the FOLFIRI-1 regimen or with another irinotecan-based regimen.
In this study, we have used the data which have been prospectively registered in the OPTIMOX1 trial in order to compare the efficacy of FOLFIRI-3 with the other irinotecanbased regimens currently used in FOLFOX-pretreated metastatic colorectal cancer patients.
patients and methods
The GERCOR OPTIMOX-1 study consisted in a randomized phase III front-line chemotherapy trial: previously untreated patients were randomized between FOLFOX4 administered every 2 weeks until progression (arm A) and FOLFOX7 for six cycles, maintenance without oxaliplatin for 12 cycles and reintroduction of FOLFOX7 (arm B) [19] . Inclusion criteria were first-line colorectal adenocarcinoma with unresectable metastases. At progression after FOLFOX or after progression in patients with grade III neuropathy, no second line was defined in the protocol, but irinotecan-based chemotherapy was recommended. Age, sex, synchronous or metachronous metastatic disease, prior adjuvant chemotherapy, performance status (PS), lactate deshydrogenase (LDH), alkaline phosphatase (ALP) and carcinoembryonic antigen (CEA) were prospectively recorded at inclusion in the OPTIMOX1 study. PS, LDH and ALP were also recorded during and at the end of the trial.
Inclusion criterion for the present study was patients receiving irinotecan-based second-line chemotherapy, with exclusion if second-line PFS was unassessable or if irinotecan-based chemotherapy was associated with bevacuzimab or cetuximab. Chemotherapy regimens were classified as follows: FOLFIRI-1, FOLFIRI-3 and other irinotecan-based regimen. Data concerning second line were prospectively registered but evaluation was not monitored. These prospectively registered data on second-line chemotherapy were type of chemotherapy regimen, date of onset, tumor response, date and reason of chemotherapy discontinuation (progressive disease or other reason), date of progressive disease and date of death. PS, LDH and ALP were considered as baseline value for the second-line chemotherapy if they were measured <6 weeks before the start of the second line. Tumor response was evaluated by investigators according to RECIST criteria which were already used in first line [19] , but was not centrally reviewed.
PFS was measured from the start of second-line chemotherapy to the date of disease progression or to the date of death if no progression. OS was measured from the start of the second-line chemotherapy to the date of death. Tumor response was defined as partial and complete responses, according to the RECIST criteria. The Kaplan-Meier method was used to estimate PFS and OS; the log-rank test was used to compare survivals. Multivariate analyses for PFS and OS were carried out by the Cox proportional hazards model. Difference between categorical variable were analyzed by chi-square tests (or Fisher's exact tests when appropriate). The logistic regression model was used for multivariate analyses of categorical variable predicting the tumor control. All the significant prognosis factors in univariate analysis were included in multivariate analysis. The calculations were carried out using the StatviewÒ software (SAS, Carry, NC). For all analyses, a P value of <0.05 was considered to be statistically significant.
results
Among the 620 patients enrolled in the OPTIMOX1 study, 413 received a second-line chemotherapy, which was based on irinotecan in 361 patients. Seventeen of the 361 patients were not included in our analysis as their second-line PFS was not assessable. Two patients who received cetuximab with irinotecan were also retrieved before the analysis. Within the 342 patients finally analyzed in this study, the irinotecan-based regimens were FOLFIRI-1 (n = 112 patients, 33%), FOLFIRI-3 (n = 109 patients, 32%) and other irinotecan-based regimens (n = 121 patients, 35%). This other irinotecan-based group was FOLFIRI-1: irinotecan 180 mg/m² on day 1 followed by 400 mg/m² bolus 5FU and 46 hours continuous 5FU. Annals of Oncology original article made of various irinotecan-based regimens: irinotecan alone (n = 32 patients, 9%), irinotecan with raltitrexed (n = 9 patients, 3%) and diverse combinations of irinotecan with 5-FU/LV or oral capecitabine (n = 80 patients, 23%). The patient characteristics of the three groups are shown in Table 1 . Although the second line of chemotherapy was the investigator's choice, patient characteristics were not statistically different between the three groups. 
Annals of Oncology original article
Tumor response (complete and partial responses) was registered for 301 patients and the response rate was 10.3% (n = 31 patients). Response rates of FOLFIRI-3, FOLFIRI-1 and other irinotecan-based regimens were 17%, 8% and 6%, respectively. Prognosis factors associated with tumor response in univariate and multivariate analysis were FOLFIRI-3 regimen (relative risk (RR) 5.4, 95% confidence interval (CI) 1.3-21, P = 0.02) and elevated ALP second line (i.e. ALP before the second-line chemotherapy) (RR 0.3, 95% CI 0.70-0.91, P = 0.04).
The median second-line PFS was 3.0 months. In univariate analysis, second-line PFS was associated with PS first line (i.e. PS before the first-line chemotherapy), LDH first line, first-line PFS, ALP second line and LDH second line and with the type of irinotecan-based chemotherapy administered (Table 2) : patients who were administered FOLFIRI-3 had a significant longer PFS (Figure 2) . This difference was also significant when the FOLFIRI-3 regimen was compared with the FOLFIRI-1 regimen only (RR 1.7, 95% CI 1.3-2.2, P = 0.001). In multivariate analysis, LDH first line and the type of irinotecanbased chemotherapy were independently associated with the second-line PFS (Table 2 ). Of note, LDH second line was the only prognostic factor of second-line PFS when only the characteristics assessed before the start of second-line chemotherapy were included in the multivariate analysis (Table 2) .
Median second-line OS, measured from the start of the second-line chemotherapy, was 9.3 months. Prognosis factors associated with second-line OS in univariate analysis were PS first line, CEA first line, ALP first line and LDH first line, PFS achieved by the first-line chemotherapy, ALP second line and LDH second line. In multivariate analysis, second-line OS was independently associated with elevated LDH first line (RR 0.41, 95% CI 0.24-0.66, P = 0.0005) and elevated ALP second line (RR 0.54, 95% CI 0.31-0.95, P = 0.048).
The toxicity of the different irinotecan-based second-line regimens was not registered neither the use of hematopoietic growth factors nor the dose density reached with the different regimens. Discontinuation of the second-line chemotherapy occurred in 10 patients (3%) for another reason than disease progression (toxicity, patient's or investigator's choice).
discussion
In this study based on prospectively registered data, the use of FOLFIRI-3 as second-line chemotherapy after oxaliplatin was independently associated with a longer PFS and higher rates of tumor response, but not with a longer OS. FOLFIRI-3 offered superior activity whatever was its comparator: FOLFIRI-1 regimen or all other irinotecan-based regimens. Our study included every assessable patient receiving an irinotecan-based cytotoxic regimen, without any other exclusion criteria than the synchronous use of cetuximab. The only significant limit to the external validity of our study is that patients were primarily enrolled in the OPTIMOX1 study, a large phase III study which included also poor prognosis and elderly patients [19] . Our results maybe therefore considered as being an accurate reflect of the irinotecan-based chemotherapy efficacy in the target population (second line). Of note, although second-line treatment was not randomized or stratified for prognostic factors, LDH first line, which was the only independent prognostic factor for second-line PFS (together with the type of second-line regimen), was not different among the three treatment groups (P = 0.42). Side-effects of the different regimens were not registered prospectively in the follow-up of the OPTIMOX1 study and cannot be compared. The toxicity of the FOLFIRI-3 regimen in oxaliplatin-pretreated patients, reported in the phase II trial [17] , was mostly neutropenia (grade 3/4 neutropenia was experienced 37% of the patients, including 5% of febrile neutropenia) and diarrhea (grade 3/4 in 23% of the patients). Of note, irinotecan doses were shrunk from 100 mg/m 2 days 1 and 3 to 80 mg/m 2 days 1 and 3 in 30% of patients included in the phase II trial because of hematological toxicity [17] . This observation support the hypothesis that FOLFIRI-3 efficacy is mostly due to irinotecan potentiation by 5-FU rather than to the 11% increase of irinotecan total dose from 180 mg/m 2 (FOLFIRI-1) to 200 mg/m 2 (FOLFIRI-3). The PFS reported in our study with FOLFIRI-3 (3.7 months) appeared slightly lower than previously reported in the phase II trial (4.7 months) [17] . In the study which has compared FOLFIRI-1 versus FOLFOX in first line, with cross-over in second line [10] , the PFS achieved by second-line FOLFIRI-1 in oxaliplatin-pretreated patients was 2.5 months, and the response rate was 4%. In the same second-line setting, the EPIC study reported that PFS achieved by irinotecan as single agent or combined with cetuximab were 2.6 and 4.0 months, respectively [10] . The response rate was 4.2% for irinotecan and 16.4% when combined with cetuximab. In the current study, second-line FOLFIRI-1 regimen was also associated with a short PFS (3.0 months) and a poor response rate (8%) in oxaliplatin-pretreated patients. Of note, a 4.2-month PFS was initially reported after 5-FU failure with a suboptimal irinotecan-based second line [8] . Altogether, these results support the hypothesis that the PFS achieved by second-line irinotecan-based regimens decreased since oxaliplatin is used in first line. original article
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As reported here, the use of the synergic effect between 5-FU (when administered before irinotecan) and irinotecan might be used to prolong the second-line PFS and enhance the response rate. The optimization of the cytotoxic regimens is critical, as the use of targeted therapies (bevacizumab, cetuximab) uniformly enhance the cytotoxic antitumor effect: the BICC-C study has demonstrated that FOLFIRI-1 remains superior to mIFL even when bevacizumab was added to these two regimens [11] . We therefore believe that FOLFIRI-3 with bevacizumab or with cetuximab regimens should be superior to their FOLFIRI-1-based (or any other irinotecan-based) counterpart. Finally, our results support the start of a randomized phase III trial comparing the two FOLFIRI regimens combined with an appropriate targeted therapy. 
